Archives

  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br Zealy RW Wrenn SP Davila S Min

    2022-07-26


    [1] Zealy RW, Wrenn SP, Davila S, Min KW, Yoon JH. microRNA-binding proteins: spec-ificity and function. Wiley Interdiscip Rev RNA 2017;8. [2] Treiber T, Treiber N, Plessmann U, Harlander S, Daiss JL, Eichner N, et al. A compen-dium of RNA-binding proteins that regulate microRNA biogenesis. Mol Cell 2017;66 (270-284 e13). [3] Gerstberger S, Hafner M, Tuschl T. A census of human RNA-binding proteins. Nat Rev Genet 2014;15:829–45. [4] Blackinton JG, Keene JD. Post-transcriptional RNA regulons affecting Forskolin and proliferation. Semin Cell Dev Biol 2014;34:44–54. [5] Vanderweyde T, Youmans K, Liu-Yesucevitz L, Wolozin B. Role of stress granules and RNA-binding proteins in neurodegeneration: a mini-review. Gerontology 2013;59: 524–33. [6] Bell JL, Wachter K, Muhleck B, Pazaitis N, Kohn M, Lederer M, et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? Cell Mol Life Sci 2013;70:2657–75.
    [7] Leontieva OV, Ionov Y. RNA-binding motif protein 35A is a novel tumor suppressor for colorectal cancer. Cell Cycle 2009;8:490–7. [8] Ennajdaoui H, Howard JM, Sterne-Weiler T, Jahanbani F, Coyne DJ, Uren PJ, et al. IGF2BP3 modulates the interaction of invasion-associated transcripts with RISC. Cell Rep 2016;15:1876–83.
    [13] Hinske LC, Galante PA, Kuo WP, Ohno-Machado L. A potential role for intragenic miRNAs on their hosts' interactome. BMC Genomics 2010;11:533. [14] Jonson L, Christiansen J, Hansen TV, Vikesa J, Yamamoto Y, Nielsen FC. IMP3 RNP safe houses prevent miRNA-directed HMGA2 mRNA decay in cancer and development. Cell Rep 2014;7:539–51.
    [25] Dickson RB, Lippman ME. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 1987;8:29–43. [26] Horie K, Urano T, Ikeda K, Inoue S. Estrogen-responsive RING finger protein controls breast cancer growth. J Steroid Biochem Mol Biol 2003;85:101–4. [27] Dickson RB, Huff KK, Spencer EM, Lippman ME. Induction of epidermal growth factor-related polypeptides by 17 beta-estradiol in MCF-7 human breast cancer cells. Endocrinology 1986;118:138–42.
    [35] Samanta S, Sharma VM, Khan A, Mercurio AM. Regulation of IMP3 by EGFR signaling and repression by ERbeta: implications for triple-negative breast cancer. Oncogene 2012;31:4689–97. [36] Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane in-tracellular estrogen receptor mediates rapid cell signaling. Science 2005;307: 1625–30.
    [37] Sakamoto H, Matsuda K, Hosokawa K, Nishi M, Morris JF, Prossnitz ER, et al. Expres-sion of G protein-coupled receptor-30, a G protein-coupled membrane estrogen re-ceptor, in oxytocin neurons of the rat paraventricular and supraoptic nuclei. Endocrinology 2007;148:5842–50.
    [38] Meyerson NR, Zhou L, Guo YR, Zhao C, Tao YJ, Krug RM, et al. Nuclear TRIM25 spe-cifically targets influenza virus ribonucleoproteins to block the onset of RNA chain elongation. Cell Host Microbe 2017;22 (627–638 e7). [39] Ito K, Suzuki T, Akahira J, Sakuma M, Saitou S, Okamoto S, et al. 14-3-3sigma in en-dometrial cancer–a possible prognostic marker in early-stage cancer. Clin Cancer Res 2005;11:7384–91. [40] Sun N, Xue Y, Dai T, Li X, Zheng N. Tripartite motif containing 25 promotes prolifer-ation and invasion of colorectal cancer cells through TGF-beta signaling. Biosci Rep 2017;37. [41] Vranic S, Gurjeva O, Frkovic-Grazio S, Palazzo J, Tawfik O, Gatalica Z. IMP3, a pro-posed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast. Appl Immunohistochem Mol Morphol 2011;19:413–6. [42] Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A. IMP3 is a novel bio-marker for triple negative invasive mammary carcinoma associated with a more ag-gressive phenotype. Hum Pathol 2009;40:1528–33.